{"id":5571,"date":"2022-08-04T00:00:00","date_gmt":"2022-10-14T16:15:38","guid":{"rendered":"https:\/\/mdbc1.wpengine.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agonis\/"},"modified":"2023-08-30T16:31:35","modified_gmt":"2023-08-30T20:31:35","slug":"gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni","status":"publish","type":"eb_course","link":"https:\/\/www.mdbriefcase.com\/fr\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/","title":{"rendered":"Gestion d&#8217;un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale  | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1"},"content":{"rendered":"<p>Cette vid\u00e9o aide les pharmaciens \u00e0 comprendre le r\u00f4le des inhibiteurs du co-transporteur sodium-glucose de type 2 (SGLT-2) et des agonistes des r\u00e9cepteurs du peptide -1 de type glucagon (GLP-1) dans la protection cardio-r\u00e9nale des personnes atteintes de diab\u00e8te de type 2. L\u2019objectif est d\u2019examiner l\u2019utilisation des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1 pour ces patients, et d\u2019aider les pharmaciens \u00e0 appliquer des conseils efficaces pour la prise en charge des personnes atteintes de diab\u00e8te de type 2 et de maladie r\u00e9nale chronique.\n<\/p>\n<hr>\n<p>\n\tCette activit\u00e9 d&#8217;apprentissage a re\u00e7u le soutien financier de Janssen Inc sous la forme d&#8217;une subvention \u00e0 l&#8217;\u00e9ducation.<\/p>","protected":false},"featured_media":459990,"comment_status":"open","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-5571","eb_course","type-eb_course","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gestion d&#039;un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1 - MDBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gestion d&#039;un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1 - MDBriefCase\" \/>\n<meta property=\"og:description\" content=\"Cette vid\u00e9o aide les pharmaciens \u00e0 comprendre le r\u00f4le des inhibiteurs du co-transporteur sodium-glucose de type 2 (SGLT-2) et des agonistes des r\u00e9cepteurs du peptide -1 de type glucagon (GLP-1) dans la protection cardio-r\u00e9nale des personnes atteintes de diab\u00e8te de type 2. L\u2019objectif est d\u2019examiner l\u2019utilisation des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/\" \/>\n<meta property=\"og:site_name\" content=\"MDBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-30T20:31:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2022\/08\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/\",\"name\":\"Gestion d'un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1 - MDBriefCase\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg\",\"datePublished\":\"2022-10-14T16:15:38+00:00\",\"dateModified\":\"2023-08-30T20:31:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg\",\"contentUrl\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg\",\"width\":600,\"height\":338},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.mdbriefcase.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Gestion d&#8217;un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#website\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/\",\"name\":\"MDBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.mdbriefcase.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#organization\",\"name\":\"MDBriefCase\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/logo.webp\",\"contentUrl\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"MDBriefCase\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gestion d'un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1 - MDBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mdbriefcase.com\/fr\/cours\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/","og_locale":"fr_CA","og_type":"article","og_title":"Gestion d'un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1 - MDBriefCase","og_description":"Cette vid\u00e9o aide les pharmaciens \u00e0 comprendre le r\u00f4le des inhibiteurs du co-transporteur sodium-glucose de type 2 (SGLT-2) et des agonistes des r\u00e9cepteurs du peptide -1 de type glucagon (GLP-1) dans la protection cardio-r\u00e9nale des personnes atteintes de diab\u00e8te de type 2. L\u2019objectif est d\u2019examiner l\u2019utilisation des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs [&hellip;]","og_url":"https:\/\/www.mdbriefcase.com\/fr\/cours\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/","og_site_name":"MDBriefCase","article_modified_time":"2023-08-30T20:31:35+00:00","og_image":[{"width":600,"height":338,"url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2022\/08\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/","url":"https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/","name":"Gestion d'un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1 - MDBriefCase","isPartOf":{"@id":"https:\/\/www.mdbriefcase.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/#primaryimage"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2022\/08\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg","datePublished":"2022-10-14T16:15:38+00:00","dateModified":"2023-08-30T20:31:35+00:00","breadcrumb":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/#primaryimage","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2022\/08\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2022\/08\/Cardiorenal-Protection-Type-2-Diabetes-Role-of-SGLT2i-GLP1-RA-694367322-25.jpg","width":600,"height":338},{"@type":"BreadcrumbList","@id":"https:\/\/www.mdbriefcase.com\/courses\/gestion-dun-cas-complexe-patient-atteint-de-diabete-de-type-2-et-de-maladie-renale-module-2-protection-cardio-renale-dans-le-diabete-de-type-2-le-role-des-inhibiteurs-du-sglt-2-et-des-agoni\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mdbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.mdbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"Gestion d&#8217;un cas complexe : patient atteint de diab\u00e8te de type 2 et de maladie r\u00e9nale | Module 2 : Protection cardio-r\u00e9nale dans le diab\u00e8te de type 2 : le r\u00f4le des inhibiteurs du SGLT-2 et des agonistes des r\u00e9cepteurs du GLP-1"}]},{"@type":"WebSite","@id":"https:\/\/www.mdbriefcase.com\/#website","url":"https:\/\/www.mdbriefcase.com\/","name":"MDBriefCase","description":"","publisher":{"@id":"https:\/\/www.mdbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mdbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.mdbriefcase.com\/#organization","name":"MDBriefCase","url":"https:\/\/www.mdbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"MDBriefCase"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/5571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=5571"}],"version-history":[{"count":0,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/5571\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media\/459990"}],"wp:attachment":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=5571"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=5571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}